Highlights:

• CSL’s transformation delivered US$176 million in cost savings, beating its FY26 target.
• Cochlear’s implant volumes rose 5%, supported by strong Nucleus Nexa adoption.
• Both healthcare leaders enter FY27 focused on restoring sustainable earnings growth.

Healthcare Stocks RallyTwo ASX healthcare heavyweights attracted strong investor attention following their FY26 results. CSL Limited (ASX: CSL) traded at a current market price (CMP) of AU$154.290, recording a gain of approximately 14.65%, while Cochlear Limited (ASX: COH) traded at AU$133.940, rising approximately 2.05%.

The contrasting share-price reactions underline a common theme: investors appear increasingly focused on whether restructuring, product momentum and cost discipline can translate into stronger earnings trajectories.CSL Reset Gains TractionCSL characterised FY26 as a reset year. At constant currency, total revenue declined 1% to US$15.37 billion, while underlying NPATA attributable to shareholders fell 2% to US$3.14 billion. Reported results were significantly weaker, with CSL recording a US$2.58 billion net loss after substantial restructuring and impairment charges.The transformation program nevertheless delivered tangible progress. CSL achieved approximately US$176 million in cost savings, ahead of target, while one-off pre-tax restructuring costs reached US$799 million. The company also plans approximately US$1.5 billion of investment to expand its US plasma manufacturing footprint.

Operationally, newer therapies provided encouraging signals. HEMGENIX sales grew 25%, while ANDEMBRY generated US$240 million in its first full year. However, FY26 impairments totalled US$7.1 billion, reflecting changes in commercial assumptions, competition and regulatory developments.

CSL Limited declared a US$1.62 per share final dividend for FY26, payable on 2 October 2026, with an ex-dividend date of 9 September 2026.Cochlear Faces Margin TestCochlear reported FY26 sales revenue of AU$2.34 billion, representing 2% constant-currency growth, while underlying net profit declined 22% to AU$322.4 million. Cochlear implant volumes increased 5% to 56,692 units, although implant revenue remained flat in constant currency.

A key positive was rapid adoption of the Nucleus Nexa System, which accounted for more than 95% of developed-market implant sales by June and supported an average 3% price increase.

However, profitability remains a key pressure point. Full-year dividends declined 20% to AU$3.45 per share, including a final dividend of AU$1.30 per share, 85% franked.FY27 Outlook Takes FocusCSL expects FY27 revenue to remain broadly in line with FY26 and underlying NPAT to grow approximately 5%. Behring is targeting mid-single-digit revenue growth, although Vifor expects an approximately 25% decline amid generic competition and product-specific headwinds.

Cochlear, meanwhile, expects low single-digit constant-currency sales growth and underlying net profit of AU$330–350 million, supported by gradual developed-market improvement, cost discipline and targeted growth investment.

The outlook for both companies therefore hinges on execution. CSL must convert restructuring into sustainable earnings recovery, while Cochlear needs Nexa adoption, referral initiatives and cost reductions to rebuild margins. Their FY26 results have reset expectations; FY27 will test whether today’s optimism can develop into durable growth.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au